I already wrote about VAXIMM AG in another sbstack.
VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.
VAXIMM also has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs.
VAXIMM’s investors include:
BB Biotech Ventures
BCM Europe
BioMed Partners
CMS
M Ventures
NEC
Sunstone Capital
BCM Europe AG, Zug
In November 2022, all shares of VAXIMM AG were sold to BCM Europe AG, Zug, Switzerland.
Looking at VAXIMM’s website and researching on Moneyhouse we find the following people at VAXIMM or formerly associated with VAXIMM.
Peter Hwang
Ralf Kubli
Prof. Dr. Dr. Tomas Dezsö Szucs
Huai Zheng Peng( Pett Woods, UK)
Dr. Markus Hosang
Cheryl Doreen Zimberlin
Mathieu William Simon
Heinz Lubenau (Neustadt an der Weinstraße)
Kuk Hyoun Hwang
Prof. Dr. Dr. Tomas Dezsö Szucs
Prof. Dr. Thomas Szucs is Professor of Pharmaceutical Medicine and Director of The Institute of Pharmaceutical Medicine / European Center of Pharmaceutical Medicine at the University of Basel. He is also a Professor and part-time lecturer for Medical Economics at the University of Zurich and a honorary professor at the University of Peking Health Science Center.
Dr. Huaizheng Peng
Dr. Huaizheng Peng is the CEO of CMS Ventures and General Manager for International Investment & Operations.
CMS Ventures, launched in 2020, is the investment arm of China Medical System Holdings Limited (CMS), a well-established, innovation-driven specialty pharma founded in 1995, and listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 867).
CMS Ventures receives support from AstraZeneca and Cambridge Judge Business School.
CMS is recognising the vibrancy and the vitality of the UK biotech and life sciences ecosystem, through financing CMS Ventures, based in Cambridge (UK), to invest (off balance sheet) up to £25m in biotech and life sciences start-ups in the UK over the next five years.
CMS Ventures provides patient capital for ambitious Biotech and Life Sciences start-ups in the 4Ds (Drugs, Devices, Diagnostics and Digital), interested in entering the Chinese market with a trusted partner of choice.
Link to Huaizheng Pen at CMS Ventures
Dr. Markus Hosang
Dr. Markus Hosang has a strong pharmaceutical and VC background and joined BioMedPartners in 2004. He was Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, managed the European office in Munich, and served on the board of several portfolio companies.
MPM Capital connects to UBS, Credit Suisse, Rocket Internet (Samwer Brothers) and Silicon Valley Bank (SVB).
Link to Dr. Markus Hosang at BioMed Partners
Cheryl Doreen Zimberlin
People at Macrophage Pharma Limited
Mark Regnerus Leonardus KRUL
Stephan CHRISTGAU
Soren Bregenholt FREDERIKSEN
Hakan GOKER
Robert Ian JAMES
Anker LUNDEMOSE
Ian Alexander Francis MISCAMPBELL
Michael MOORE
Steven John POWELL
Venkateshwar Alumalla REDDY
Link to Macrophage Pharma
Mathieu William Simon
?
Kuk Hyoun Hwang
Kuk Hyoun Hwang, Chief Executive Officer, Bellevue Life Sciences Acquisition Corp
Bellevue Life Sciences Acquisition Corp
Link to Bellevue Life Sciences Acquisition Files for $60M IPO
Dr. Heinz Lubenau
Dr. Heinz Lubenau, General Manager and Head of Development at VAXIMM GmbH.
Link to Healthcaree Industry Baden-Württemberg VAXIMM: Vaccines that impede cancer growth
This substack should cover all the stakeholders involved at VAXIMM. I will get into more detail in another substack.